The pharmacokinetics of losartan in renal insufficiency

Abstract

The steady-state areas under the curve of losartan and E3174 are not significantly changed with renal impairment. The renal clearance of losartan decreases with renal impairment but since only a small percentage of the dose is ordinarily eliminated by the kidney, the demonstrated reduction in clearance is clinically irrelevant. The renal clearance of E3174 also decreases with renal impairment, but the steady-state area under the curve does not increase with increasing degrees of renal insufficiency. These pharmacokinetic alterations do not warrant dose adjustment in the face of renal insufficiency.